Cellectis Says Phase 1 Lasme-cel Study Shows 100% Response Rate in B-Cell Leukemia Patients
Cellectis (CLLS) said Thursday that data from a phase 1 trial of lasme-cel in relapsed/refractory B-
Keep reading this article with Yahoo Finance Plus Silver
Silver
- Premium news Full access to Financial Times and MT Newswires articles
- Stock picks Expert picks from Motley Fool, Zacks, and Moby
- Research reports Expert analysis from Morningstar and Argus
